CoDiagnostics Partners with Arabian Eagle to Expand in Middle East with CoMira Diagnostics

CoDiagnostics Expands Global Reach with Strategic Partnership in the Middle East

CoDiagnostics, Inc., a pioneering molecular diagnostics company based in Utah, is solidifying its position in the global diagnostics market through a new strategic partnership with Arabian Eagle in Saudi Arabia. This collaboration aims to establish CoMira Diagnostics, a venture dedicated to deploying the company’s Co-Dx™ PCR platform across the Middle East. The Co-Dx PCR platform is designed for advanced diagnostic testing, particularly for detecting and analyzing nucleic acids like DNA and RNA, making it a valuable tool in the fight against infectious diseases and for genetic marker identification. As the company prepares for the regulatory review of its products, including the PCR Home™ and PCR Pro™, this partnership is expected to enhance accessibility to its innovative diagnostic solutions in a region with growing healthcare demands.

The establishment of CoMira Diagnostics represents a significant step for CoDiagnostics as it aims to expand its footprint beyond domestic markets. By leveraging local expertise and infrastructure through Arabian Eagle, CoDiagnostics is positioning itself to meet the increasing demand for state-of-the-art diagnostic technologies in the Middle East. The partnership highlights the company's commitment to addressing global health challenges by providing advanced molecular diagnostic tools that can rapidly identify infectious diseases, critical for managing public health crises effectively. Furthermore, this collaboration underscores CoDiagnostics' strategic vision of fostering international partnerships that not only enhance its product deployment but also contribute to improved healthcare outcomes in underserved regions.

In addition to this partnership, CoDiagnostics is actively engaging with stakeholders through a virtual fireside chat scheduled for November 5, 2025. CEO Dwight Egan will lead the discussion, focusing on growth initiatives and the company's strategic direction, particularly in light of the recent developments with CoMira Diagnostics. Participants will have the opportunity to submit questions, fostering an interactive environment that encourages dialogue about the company's innovative approaches and future plans. This event is part of CoDiagnostics' broader strategy to maintain transparency and engagement with its investors and partners as it expands its global presence.

CoDiagnostics, recognized for its proprietary technology and advanced diagnostic capabilities, continues to navigate the regulatory landscape while preparing to launch its products in new markets. The company's focus on innovation and strategic partnerships positions it well to address the evolving needs of the global healthcare community.